Tailored Systemic Therapy for Colorectal Cancer Liver Metastases.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
29 Oct 2021
Historique:
received: 01 10 2021
revised: 27 10 2021
accepted: 27 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 21 12 2021
Statut: epublish

Résumé

Liver metastases are the most common site of metastatic spread in colorectal cancer. Current treatment approaches involve effective systemic therapies in combination with surgical and/or interventional strategies. Multimodal strategies greatly improved clinical outcomes of patients with metastatic colorectal cancer over the last decades. Identification of predictive and prognostic biomarkers helped to comprehensively refine individual targeted treatment approaches and resulted in median overall survival rates of 30 months or longer. Current guidelines, thus, recommend treatment selection according to patients' performance status, tumor localization and stage as well as the tumor's molecular and genetic status. Here, we outline the latest developments in molecular decision-making for patients with upfront resectable, potentially or initially unresectable and non/never-resectable colorectal cancer liver metastases.

Identifiants

pubmed: 34769209
pii: ijms222111780
doi: 10.3390/ijms222111780
pmc: PMC8584068
pii:
doi:

Substances chimiques

Immune Checkpoint Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

N Engl J Med. 2012 Feb 23;366(8):707-14
pubmed: 22356324
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Lancet Oncol. 2010 Jan;11(1):38-47
pubmed: 19942479
Ann Surg Oncol. 2013 Dec;20(13):4289-97
pubmed: 23955585
Cancers (Basel). 2019 Jul 04;11(7):
pubmed: 31277449
J Cancer Res Clin Oncol. 2015 Mar;141(3):515-22
pubmed: 25230900
Lancet Oncol. 2014 May;15(6):601-11
pubmed: 24717919
Cancer Control. 2021 Jan-Dec;28:10732748211041221
pubmed: 34666555
Anticancer Res. 2011 Dec;31(12):4581-7
pubmed: 22199334
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Crit Rev Oncol Hematol. 2018 Oct;130:13-26
pubmed: 30196908
Ann Oncol. 2015 Oct;26(10):2092-7
pubmed: 26153495
Lancet. 2015 May 9;385(9980):1843-52
pubmed: 25862517
Z Gastroenterol. 2017 Dec;55(12):1344-1498
pubmed: 29212104
J Clin Oncol. 2013 Jun 1;31(16):1931-8
pubmed: 23569301
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
J Clin Oncol. 2015 Mar 1;33(7):692-700
pubmed: 25605843
Ann Oncol. 2015 Jan;26(1):13-21
pubmed: 25115304
J Clin Oncol. 2016 Jan 20;34(3):227-34
pubmed: 26573078
J Hematol Oncol. 2018 Mar 15;11(1):39
pubmed: 29544515
Br J Surg. 2015 Sep;102(10):1175-83
pubmed: 26206254
World J Gastroenterol. 2016 Jan 14;22(2):519-33
pubmed: 26811604
Ann Oncol. 2014 Jul;25(7):1346-1355
pubmed: 24718886
Br J Surg. 2019 Dec;106(13):1837-1846
pubmed: 31424576
Methods. 2013 Jan;59(1):116-25
pubmed: 23079397
Ann Oncol. 2015 Apr;26(4):702-708
pubmed: 25538173
Lancet Oncol. 2016 Jun;17(6):738-746
pubmed: 27108243
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
Eur J Cancer. 2015 Mar;51(5):587-94
pubmed: 25673558
BMC Cancer. 2020 May 19;20(1):448
pubmed: 32429931
Br J Surg. 2019 Sep;106(10):1283-1297
pubmed: 31216061
Pathol Res Pract. 2020 Oct;216(10):153130
pubmed: 32853954
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Ann Oncol. 2019 Nov 1;30(11):1796-1803
pubmed: 31868905
Lancet Oncol. 2015 May;16(5):499-508
pubmed: 25877855
Ann Oncol. 2014 May;25(5):1018-25
pubmed: 24585720
Expert Rev Mol Diagn. 2020 Oct;20(10):1051-1062
pubmed: 33138648
BMC Cancer. 2019 Aug 1;19(1):758
pubmed: 31370815
Eur J Cancer. 2017 Aug;81:191-202
pubmed: 28633089
J Clin Oncol. 2015 Dec 1;33(34):4032-8
pubmed: 26460303
J Clin Med. 2020 Oct 31;9(11):
pubmed: 33142689
Cancer. 2011 Oct 15;117(20):4623-32
pubmed: 21456008
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
J Clin Oncol. 2020 Jan 1;38(1):11-19
pubmed: 31725351
Drugs Today (Barc). 2019 Nov;55(11):683-693
pubmed: 31840683
Ann Surg. 2018 Nov;268(5):845-853
pubmed: 30303876
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9
pubmed: 25190710
Ann Surg. 2017 Oct;266(4):641-649
pubmed: 28657938
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Int J Cancer. 2016 Aug 1;139(3):647-56
pubmed: 26991344
Minerva Gastroenterol Dietol. 2020 Jun;66(2):93-95
pubmed: 31347340
Eur J Cancer. 2014 Jan;50(2):320-31
pubmed: 24140268
Surgery. 2017 May;161(5):1255-1265
pubmed: 28081953
Eur J Immunol. 2017 May;47(5):765-779
pubmed: 28393361
Br J Cancer. 2019 Jul;121(3):222-229
pubmed: 31285591
Eur J Cancer. 2016 May;59:13-21
pubmed: 26994469
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):162-171
pubmed: 29254887
J Am Coll Surg. 2019 Dec;229(6):523-532.e2
pubmed: 31520695
Cardiovasc Intervent Radiol. 2015 Dec;38(6):1523-31
pubmed: 25799948
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Eur J Cancer. 2012 Jul;48(10):1466-75
pubmed: 22446022
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
J Clin Oncol. 2014 Jul 20;32(21):2240-7
pubmed: 24687833
Cancer Discov. 2012 Mar;2(3):227-35
pubmed: 22448344
Ann Surg Oncol. 2016 Aug;23(8):2635-43
pubmed: 27016292
Ann Oncol. 2017 Aug 1;28(8):1713-1729
pubmed: 28407110
Innov Surg Sci. 2018 May 07;3(2):85-86
pubmed: 31579770
Pharmacogenomics J. 2014 Apr;14(2):120-9
pubmed: 23529007
Eur Radiol. 2021 Apr;31(4):2242-2251
pubmed: 32960329
Surg Oncol. 2018 Jun;27(2):280-288
pubmed: 29937183
Surgeon. 2015 Apr;13(2):83-90
pubmed: 25257725
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):143-145
pubmed: 29254888
Clin Cancer Res. 2007 Jun 1;13(11):3221-8
pubmed: 17545526
Lancet Oncol. 2020 Mar;21(3):398-411
pubmed: 32014119
J Natl Compr Canc Netw. 2019 May 1;17(5.5):599-601
pubmed: 31117039
J Clin Oncol. 2019 Dec 10;37(35):3401-3411
pubmed: 31609637
Br J Cancer. 2015 Jun 9;112(12):1888-94
pubmed: 25989278
N Engl J Med. 2013 Sep 12;369(11):1023-34
pubmed: 24024839
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050

Auteurs

Carolin Czauderna (C)

Department of Medicine I, University Medical Center Schleswig-Holstein-Campus Lübeck, 23558 Lübeck, Germany.

Kim Luley (K)

Department of Hemato-Oncology, University Medical Center Schleswig-Holstein-Campus Lübeck, 23558 Lübeck, Germany.

Nikolas von Bubnoff (N)

Department of Hemato-Oncology, University Medical Center Schleswig-Holstein-Campus Lübeck, 23558 Lübeck, Germany.

Jens U Marquardt (JU)

Department of Medicine I, University Medical Center Schleswig-Holstein-Campus Lübeck, 23558 Lübeck, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH